drugset / Trial / NCT01113541
One-Year Trial of Oral Ziprasidone in Bipolar Patients With Metabolic Syndrome
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to explore the impact of Ziprasidone HCl on the distribution of metabolic syndrome (MS) risk factors in a population of Bipolar patients presenting with glucose intolerance, dyslipidemia and/or elevated waist circumference associated with their current antipsychotic medication.
Timeline
- Start
- 2010-07
- Primary completion
- 2011-02
- Completion
- 2011-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ziprasidone | Small molecule | 20 mg | Oral |
| Subject | Ziprasidone | Small molecule | 80 mg | Oral |